Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Syndax Pharmaceuticals Head of R&D and CMO Nicholas A.J. Botwood reported an exercise-and-sell pattern in company stock. On June 11–12, he exercised stock options to acquire a total of 53,750 shares of common stock at $13.82 per share and sold 65,515 shares in open-market transactions around $18 per share. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 60,885 common shares and has 16,537 vested and 289,413 unvested options to purchase additional shares.

Insider Trade Summary 10b5-1

Net Seller: 65,515 shares ($1,183,643)

Net Sell 6 txns

Insider Botwood Nicholas A.J.

Role Head of R&D, CMO

Sold 65,515 shs ($1.18M)

Type	Security	Shares	Price	Value
Exercise	Stock options (Right to buy)	31,235	$0.00	--
Exercise	Common Stock	31,235	$13.82	$432K
Sale	Common Stock	31,235	$18.14	$567K
Exercise	Stock options (Right to buy)	22,515	$0.00	--
Exercise	Common Stock	22,515	$13.82	$311K
Sale	Common Stock	34,280	$18.00	$617K

Holdings After Transaction: Stock options (Right to buy) — 0 shares (Direct, null); Common Stock — 92,120 shares (Direct, null)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested. These transactions were executed in multiple trades at prices ranging from $17.31 to $18.10. The price reported above reflects the weighted-average sale price of all transactions executed on that date. These transactions were executed in multiple trades at prices ranging from $18.00 to $18.32. The price reported above reflects the weighted-average sale price of all transactions executed on that date. The shares sold in this transaction were fully vested.

Key Figures

Shares sold: 65,515 shares Sale prices: $18.00 and $18.14/share Options exercised: 53,750 shares +4 more

7 metrics

Shares sold 65,515 shares Open-market sales on June 11–12

Sale prices $18.00 and $18.14/share Weighted-average sale prices on June 11–12

Options exercised 53,750 shares Options exercised at $13.82/share

Common shares held 60,885 shares Direct holdings after transactions

Vested options remaining 16,537 options Vested, immediately exercisable options after transactions

Unvested options remaining 289,413 options Unvested options to purchase common stock

Net share change -65,515 shares Net buy/sell direction reported as net-sell

Key Terms

Rule 10b5-1 plan, weighted-average sale price, stock options (Right to buy), vested and immediately exercisable, +1 more

5 terms

Rule 10b5-1 plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted-average sale price financial

"The price reported above reflects the weighted-average sale price of all transactions executed on that date."

stock options (Right to buy) financial

"Stock options (Right to buy)"

vested and immediately exercisable financial

"a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable"

unvested financial

"a total of 289,413 options to purchase shares of common stock that have not yet vested."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 05:10 PM Accepted by SEC EDGAR 06/12/2026 - 05:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Botwood Nicholas A.J.

(Last)

(First)

(Middle)

730 THIRD AVENUE

FLOOR 9

(Street)

NEW YORK

10017

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Syndax Pharmaceuticals Inc [ SNDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Head of R&D, CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		M		22,515	A	$13.82	95,165	D
Common Stock	06/11/2026		S⁽¹⁾		34,280	D	$18⁽²⁾	60,885	D
Common Stock	06/12/2026		M		31,235	A	$13.82	92,120	D
Common Stock	06/12/2026		S⁽¹⁾		31,235	D	$18.14⁽³⁾	60,885	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock options (Right to buy)	$13.82	06/11/2026		M		22,515		⁽⁴⁾	05/31/2035	Common Stock	22,515	$0	0	D
Stock options (Right to buy)	$13.82	06/12/2026		M		31,235		⁽⁴⁾	05/31/2035	Common Stock	31,235	$0	0	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested.

2. These transactions were executed in multiple trades at prices ranging from $17.31 to $18.10. The price reported above reflects the weighted-average sale price of all transactions executed on that date.

3. These transactions were executed in multiple trades at prices ranging from $18.00 to $18.32. The price reported above reflects the weighted-average sale price of all transactions executed on that date.

4. The shares sold in this transaction were fully vested.

	/s/ Michael A. Metzger, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Syndax (SNDX) report for Nicholas Botwood?

Syndax reported that Head of R&D and CMO Nicholas Botwood exercised options for 53,750 shares and sold 65,515 common shares. The sales, executed around $18 per share, were carried out under a pre-arranged Rule 10b5-1 trading plan.

How many Syndax (SNDX) shares did Nicholas Botwood sell and at what prices?

Nicholas Botwood sold 65,515 Syndax common shares in two open-market transactions. One sale covered 34,280 shares at $18.00 per share; another covered 31,235 shares at a weighted-average price of $18.14 per share.

What options did Nicholas Botwood exercise in this Syndax (SNDX) Form 4?

Botwood exercised stock options to buy 22,515 shares and 31,235 shares of Syndax common stock, both with a $13.82 exercise price. These exercises converted previously granted options into common shares that were then partly sold in the market.

How many Syndax (SNDX) shares does Nicholas Botwood hold after the transactions?

Following the reported option exercises and sales, Nicholas Botwood directly holds 60,885 shares of Syndax common stock. This figure reflects his remaining equity stake after the June 11–12 open-market dispositions disclosed in the Form 4 filing.

What remaining options does Nicholas Botwood have in Syndax (SNDX)?

After the reported exercises, Botwood retains 16,537 vested options and 289,413 unvested options to purchase Syndax common stock. The vested options are immediately exercisable, while the unvested options are scheduled to vest over time under their grant terms.

Were the Syndax (SNDX) insider sales by Nicholas Botwood pre-planned?

Yes. A footnote states the sales were effected under a Rule 10b5-1 trading plan adopted by Nicholas Botwood. Such plans pre-schedule trades, making the timing more mechanical and less reflective of short-term views on Syndax’s share price.